



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/802,315	03/08/2001	Archie Woodworth	1417 Y P 516	5264

7590 10/19/2006

Baxter International Inc.  
One Baxter Parkway  
DF2-2E  
Deerfield, IL 60015

EXAMINER

MCKANE, ELIZABETH L

ART UNIT	PAPER NUMBER
----------	--------------

1744

DATE MAILED: 10/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

09/802,315

Applicant(s)

WOODWORTH ET AL.

Examiner

Leigh McKane

Art Unit

1744

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 01 August 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 76-78, 80-86, 89-94 and 105-108 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 76-78, 80-86, 89-94 and 105-108 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 08 March 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

***Claim Rejections - 35 USC § 102***

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 105, 106, and 108 are rejected under 35 U.S.C. 102(b) as being anticipated by Erbe et al. (U.S. Patent No. 6,800,245).

Erbe et al. teaches a method for producing sterile prefilled syringe bodies wherein the method of Erbe et al. includes providing a syringe body (cartridge), transferring the body to a sterile environment (isolator) 70, and sterilizing the cartridge with e-beam radiation in a step between providing the cartridges and transferring them to the sterile environment. Within the sterile environment, they are filled and sealed. See Figure 1; col.4, lines 34-37; col.6, lines 3-20; col.8, lines 17-20 and 30-32; col.12, lines 2-5, 19-27, 39-46.

***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claim 107 is rejected under 35 U.S.C. 103(a) as being unpatentable over Erbe et al..

Erbe et al. clearly teaches that the cartridges (syringes) are sterilized in a location other than the sterile isolator. Note that Erbe et al. discloses that only the steps of filling, assembling the piston, packaging the filled cartridges, and sealing the packages occur in the sterile isolator. See col.6, lines 14-18. Therefore, the cartridges *must* be transferred between the location where they are sterilized by e-beam radiation and the location where they are filled (isolator). It would have been obvious to one of ordinary skill in the art to accomplish this transfer in a sterile manner otherwise the sterile condition of the cartridges would have been compromised.

5. Claims 76-78, 82-86, and 89-91 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lawecky et al. (US 6,145,277) in view of Porfano et al (U.S. Patent No. 6,164,044) and Erbe et al. (U.S. Patent No. 6,800,245).

With respect to claims 76-78 and 89, Lawecky et al. teaches a method of in-line, continuous production of sterile, prefilled syringe bodies. The method of Lawecky et al. includes the steps of injection molding the syringe bodies (col.2, lines 12-13), arranging the syringe bodies on a conveyor (col.2, lines 15-17), sterilizing the syringe bodies using a sterilizing gas (col.2, lines 3-5), transferring the syringe bodies to an inspection station and a filling and assembly isolation area followed by a packaging station. See col.2, lines 26-36 and lines 42-48. The entire enclosure defines a class 100 environment. See col.1, lines 52-58. Lawecky et al. further discloses that “preferably no humans are employed” as the process is substantially automated or accomplished by robots. Lawecky et al. does not disclose that the syringe bodies are formed of cyclic olefin copolymer or sterilizing the syringe bodies with e-beam radiation.

Erbe et al. teaches a method of sterilizing an injectable pharmaceutical wherein the cartridges (syringes), caps, and plunger pistons are sterilized using a dose of e-beam radiation,

Art Unit: 1744

transferred into a sterile isolator (which is class 100 or greater), filled with a sterile fluid while within the sterile environment, and sealed within the sterile environment. See Figure 1; col.4, lines 34-37; col.6, lines 320; col.8, lines 17-20 and 30-32; col.12, lines 2-5, 19-27, 39-46. As Erbe et al. has evidenced that e-beam sterilization is a suitable alternative to gas sterilization, it would have been an obvious modification to the method of Laweck et al..

Porfano et al discloses that it was known in the art at the time of the invention to form containers intended for sterilizing and filling, of a cyclic olefin copolymer. See col.6, lines 44-47. As Porfano et al teaches that cyclic olefin copolymers do not require a clarifying agent, they would have been an economical choice for the syringes of Laweck et al..

As to claims 82 and 86, although not expressed by Laweck et al., it would have been obvious to fill the syringes immediately after sterilization, in order to reduce the likelihood of contamination of the syringes prior to filling.

With respect to claim 83-85, Laweck et al. teaches that the syringes, filled and unfilled, are for medical use. Therefore, it is deemed obvious to employ the general aseptic packaging techniques of Laweck et al. for various sterile injectables, such as sterile water, and to maintain a suitable injection pH when doing so.

As to claims 90-91, Laweck et al. discloses that the syringes may be assembled. Erbe et al. teaches that syringes are known to include caps and plunger pistons, which complete the assembled syringe. It would have been obvious to provide a step of assembling the syringe body of Laweck et al. with a cap and plunger, as these are known and necessary components of the syringes.

Art Unit: 1744

6. Claims 80 and 81 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lawecky et al. in view of Porfano et al. and Erbe et al., as applied to claim 76 above, and further in view of Nablo (U.S. 3,780,308).

The combination of Lawecky et al. with Erbe et al. does not disclose an irradiation dose for e-beam radiation of the syringes. Nablo teaches employing a radiation dose of 15 kGy for container sterilization. However, Nablo also employs high dose rates, such as  $10^{14}$  rad/sec ( $10^9$  kGy/sec). See col.5, lines 16-19. It is deemed obvious to optimize and even increase the radiation dose based upon the expected level of contamination, as such is easily obtained by routine experimentation.

7. Claim 92-94 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lawecky et al. in view of Porfano et al. and Erbe et al., as applied to claim 91 above, and further in view of Liebert et al. (US 5,207,983).

With respect to claim 92, the combination of Lawecky et al. with Erbe et al. does not disclose that the syringe plunger has a plunger rod. However, Liebert et al. evidences that this configuration is known in the art (col.6, lines 28-38) and absent unexpected results, it would have been obvious to use this type of syringe plunger in the method of the combination *supra*.

As to claim 93, while Lawecky et al. is silent with respect to terminally sterilizing the filled syringes, Liebert et al. teaches that it was known in the art at the time of the invention to terminally sterilize a prefilled syringe. It is deemed obvious to add the additional step of terminal sterilization to the method of Lawecky et al. in order to add a factor of safety to the sterilization method.

With respect to claim 94, Laweck et al. teaches packaging the prefilled syringes (col.2, lines 46-49). It is deemed obvious to also label the syringes, as is known in the art, to identify the product within the syringe.

### *Response to Arguments*

8. Applicant's arguments filed 1 August 2006 have been fully considered but they are not persuasive.

9. Applicant submits that Erbe fails to teach that cartridge irradiation occurs while the cartridges are being transferred into an isolator. The Examiner strongly disagrees. It appears that applicant is attempting to read certain specific limitations into the phrase “during the transferring.” The broadest reasonable interpretation of “during the transferring” is that the syringes are sterilized *at some time* in the moving of the syringes from the location where they are provided and the sterile environment. In Erbe, the syringes are provided and are moved into the sterile environment. At some time in the moving of the syringes from one location to another, they are sterilized. Thus, Erbe meets the claim limitation.

10. With respect to the rejections relying upon Laweck et al., Applicant alleges that Laweck et al. teaches away from transferring unwrapped syringe bodies into a sterile environment as recited by claim 76. Again, the Examiner respectfully disagrees with Applicant. Firstly, the portions of Laweck et al, to which Applicant refer, wherein the syringes are triple bagged, occur *after* the syringes have been filled, sealed, and packaged. At this point, the syringes are not being transferred to a sterile environment – they are being transferred *out* of the sterile

environment. Lawecki et al. discloses transferring unwrapped syringe bodies from the sterilizing location to the sterile environment for filling.

### ***Conclusion***

11. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leigh McKane whose telephone number is 571-272-1275. The examiner can normally be reached on Monday-Friday (5:30 am-2:00 pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gladys Corcoran can be reached on 571-272-1214. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1744

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

  
**Leigh McKane**  
**Primary Examiner**  
**Art Unit 1744**

elm  
14 October 2006